Results
1 -
2 of
2Anaplastic Thyroid Cancer, Endocrine Neoplasia Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer, Investigational New Drugs